Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study NOG112264, a Phase II Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis

NCT01753076 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01753076
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01753076 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study NOG112264, a Phase II Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
December 20, 2012
Completion date
January 22, 2015
Enrollment
304 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

amyotrophic lateral sclerosis